EyePoint's Stock Soars 195% in Three Years Despite Persistent Losses, Sparking Investor Debate
While EyePoint Pharmaceuticals (EYPT) shares have retreated 23% this month, long-term shareholders are still sitting on massive gains. The biotech's 195% three-year surge, despite ongoing losses, highlights a classic market puzzle: balancing current financials with future potential.